A Phase I Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Trial Profile

A Phase I Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs IMC gp100 (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Immunocore
  • Most Recent Events

    • 11 Dec 2017 According to a Immunocore media release, IMCgp100 has been granted Promising Innovative Medicines (PIM) designation by United Kingdom's Medicines and Healthcare Products Regulatory Agency for the treatment of metastatic uveal melanoma patients based on the data from this trial.
    • 13 Nov 2017 According to an Immunocore media release, results from this and another phase I trial were presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top